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Summary: The concentrations of selenium and lipid peroxides and the catalytic activity of glutathione
peroxidase were measured in the blood of 6 children (6 — 16 years of age) and 8 adults (17 — 27 years old)
with Down's syndrome (trisomy 21). The values were compared with those for a control group of age-matched
normal people.
The selenium concentration in whole blood, erythrocytes and plasma was significantly lower in trisomy 21
patients than in normal subjects (p < 0.001) in both age groups. No statistically significant differences were
observed in selenium concentration in whole blood, erythrocytes and plasma between children and adults in
the Down's syndrome group. Glutathione peroxidase catalytic activity in erythrocytes was significantly higher
in Down's syndrome children than in healthy children (p < 0.001). Plasma glutathione peroxidase catalytic
activity in both investigated age groups was statistically considerably lower in the Down's syndrome patient
group. The concentration of lipid peroxides, expressed as the malondialdehyde concentration, is lower in
Down's syndrome patients. No correlation between selenium concentration, glutathione peroxidase catalytic
activity and amount of lipid peroxides was found in the trisomy 21 patient group.
Introduction _, , . ._ N . * ,Selenium (Se) is necessary for the enzymatic activity
Many papers have reported investigations of oxygen of glutathione peroxidase — it is the component of
metabolism in trisomy 21 patients (Down's syndrome) the catalytic site of the enzyme (5) and probably
and there have been suggestions that some of the stimulates glutathione peroxidase synthesis in humans
pathological symptoms of this disease, for example (6) and animals (7). The gene for glutathione perox-
premature ageing, or specific brain lesion, result from idase synthesis is situated on chromosome No. 3 and
the increase of the oxidative damage inside the cells for this reason the increase of the glutathione perox-
(1, 2). One of the observed and probable defence idase activity in trisomy 21 patients is not caused by
mechanisms of the cell against the oxidative damage a gene dosage effect (8). The higher activity of the
is the increase of catalytic activity of enzymes coun- enzyme in the cells may be explained as one of the
teracting toxic oxygen derivatives: Superoxide dis- mechanisms controlling the response to an accelera-
mutase (EC 1.15.1.1), and glutathione peroxidase (EC tion of oxidative processes inside the trisomic 21 cells.
1.11.1.9) (2, 3). Glutathione peroxidase catalyses the
reduction of hydrogen peroxide and organic hydro- Anneren et al. (9) observed that the Superoxide con-
peroxides to alcohols of lower toxicity, thus forming centration in polymorphonuclear neutrophils from
the first line of defence against peroxidative damage Down's syndrome patients is only about 75% of that
of unsaturated lipids (4). in healthy individuals. This decrease in Superoxide
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concentration is probably due to an increased trans-
formation of Superoxide anion to H2O2, and might
be one of the possible explanations for the fact that
glutathione peroxidase activity is increased in Down's
syndrome patients.
The erythrocyte glutathione peroxidase catalytic ac-
tivity in trisomy 21 patients, however, remains a mat-
ter of controversy: normal activities have been claimed
by some authors (1, 10), and elevated activities by
others (2, 11, 12, 13, 14). Until now there has been
only one report of an increase of lipid peroxide con-
centration in the plasma of patients with Down's
syndrome (13).
The aim of our work was to determine relationships
between glutathione peroxidase activity and selenium
and lipid peroxide concentrations in Down's syndrome
patients in 2 age groups, in comparison with age-
matched normal people.
Materials and Methods
The investigation was carried out upon 14 Down's syndrome
patients (8 females, 6 males with karyotypes 47,XX 4- 21 and
47,XY + 21, respectively) living in Lodz. The trisomy 21 pa-
tients were out-patients who visit the clinics regularly. The
control group consisted of 110 people aged 6 — 30 years (57
males and 53 females) from Lodz and its surroundings.
All patients and controls had normal haematological values
(haemoglobin concentration, haematocrit, red blood cell
count). Venous blood samples were collected in heparinized
tubes free from trace-elements. Plasma and buffy coat were
removed after centrifugation and red blood cells were washed
twice with isotonic saline. Pure erythrocytes were suspended in
9 g/1 saline, then lysed by freezing and thawing.
The activity of glutathione peroxidase in plasma and erythro-
cytes was estimated by the Paglia & Valentine method (15)
modified by Hopkins & Tudhope (16), with the use of r-butyl
hydroperoxide as a substrate.
Glutathione peroxidase activity was defined as the amount of
enzyme which catalyses oxidation of 1 μπιοί of NADPH per
min per g of Hb (or 1 of plasma). Selenium was determined by
the fluorimetric method of Watkinson (17) with 2,3-diamino-
naphthalene. Quality control was monitored by the use of the
International Atomic Energy Agency dried blood standard (Α-
Ι 3) and the selenium content (mean ± SD) determined in this
study was 255 ±15 μg/kg the assigned value being 240 Mg/kg.
Se concentration was expressed in μg of selenium per 1 of whole
blood, plasma or pure packed erythrocytes. The concentration
of peroxides of higher polyunsaturated fatty acids was deter-
mined in plasma by the Yagi method (18) with 2-thiobarbituric
acid. 1,1,3,3-Tetraethoxypropane (0.5 mol/1) was used as a
standard. The concentration of lipid peroxides in blood plasma
was expressed as the amount of malondialdehyde per 1 of
plasma.
Haemoglobin concentrations were determined by the haemi-
globin cyanide method. Differences between group means were
tested by the Student t-test.
Results
The results are presented in table 1.
Selenium concentration in whole blood, erythrocytes
and in plasma was significantly lower in the Down's
syndrome patients than in normal subjects (p < 0.001
in all cases) in both investigated age groups.
Tab. 1. Lipid peroxides and selenium concentration and glutathione peroxidase activity in blood of patients with Ztawi's syndrome





























101.8 ± 16.2 (77)
142.2 ± 31.5 (74)
76.6 ± 13.1 (77)
18.1 ± 2.4 (78)
203.1 ±26.3 (78)
4.14 ± 1.05 (68)
0.46 ± 0.06
118.1 ±16.1 (32)
167.3 ± 33.3 (32)
90.2 ± 17.5 (32)
18.4 ± 4.5 (32)
236.3 ± 63.4 (32)
4.04 ± 0.89 (9)
0.36 ± 0.04
70.2 ± 12.7 (6)
116.5 ±23.8 (6)
47.8 ±11.9 (6)
24.1 ± 3.2 (6)
129.1 ± 29.0 (6)
3.06 ± 0.78 (6)
0.39 ± 0.04
68.1 ± 14.3 (8)
110.3 ±37.5 (8)
46.4 ±11.4 (8)
19.3 ± 5.1 (8)
156.1 ±34.4 (8)
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In the control group (aged 17 — 27 years) the selenium
concentrations in whole blood, erythrocytes and
plasma were statistically higher than in the group of
healthy children (6-16 years) (p < 0.001). No statis-
tical differences between children (6 — 16 years) and
adults (17—27 years) were found in the trisomy 21
group with respect to the selenium concentration in
whole blood, erythrocytes and plasma.
No sex differences between the control and patient
groups were found. Glutathione peroxidase activity
in erythrocytes is significantly increased in trisomy 21
children (p < 0.001), but in the adult group no sta-
tistically significant differences were noticed between
the Down's syndrome patients and control group.
However, the plasma enzyme activity in both tested
groups is statistically significantly decreased in the
Down's syndrome patient group (p < 0.001 in both
groups). The concentration of lipid peroxides, as ex-
pressed by malondialdehyde, is lower in trisomy 21
patients. This decrease is statistically significant in the
group of children and adults: p < 0.02 and p < 0.005,
respectively. No correlation was found between lipid
peroxide concentration- and the corresponding gluta-
thione peroxidase activity in erythrocytes and plasma
in the Down's syndrome patient group.
Discussion
Earlier investigations have demonstrated a trend to-
wards increasing erythrocyte glutathione peroxidase
activity in trisomy 21 patients as compared with
healthy control groups (2, 9, 11 — 14). In our investi-
gation we have shown a 30% increase of glutathione
peroxidase catalytic activity in erythrocytes of chil-
dren with Down's syndrome as compared with an age-
matched control group. In adult patients the eryth-
rocyte glutathione peroxidase activity increases by
5%. These values are comparable with those obtained
by Neve et al. (10), and are slightly lower than those
reported earlier in which glutathione peroxidase ac^
tivity in Down's syndrome patients was found to be
139-156% ofthat in healthy controls (11,12). Prob-
ably the increase of glutathione perpxidase activity in
erythrocytes is the secondary result of a regulatory
mechanism involving an increased activity of super-
oxide dismutase and intensified production of H2O2
in trisomy 21 cells (9), Elevated glutathione peroxi-
dase activity in Down's syndrome patients could be a
useful protective mechanism against peroxidative cell
damage.
The increase of glutathione peroxidase activity in the
erythrocytes of Down's syndrome patients does not
result in the increase of Se concentration. Whole
blood, erythrocyte and plasma selenium was signifi-
cantly lower in Down's syndrome patients than in
normal subjects in both tested groups. The absence
of any change of Se concentrations in Down's syn-
drome erythrocytes can be explained by the fact that
selenium, in the form of Se-glutathione peroxidase,
constitutes only 10% of the total cell selenium (9).
The low selenium concentration in Down's syndrome
patients is not due to an insufficiency of selenium
intake (1, 14, 20). Belgium investigators (14, 20) have
shown that control groups receiving the same food as
the Down's syndrome patients have a significantly
higher Se concentration in plasma. In erythrocytes
the Se concentration increase is not significant. The
observed decrease of Se concentration in trisomy 21
patients has no influence upon its bioavailability, as
the activity of glutathione peroxidase does not differ
from that of the control group (12, 13, 14, 20).
As it has been shown that the concentrations of cop-
per and zinc in erythrocytes of Down's syndrome of
patients show a statistically significant increase (1,10,
14, 21). The decreased concentration of selenium in
erythrocytes may be explained as a result of the an-
tagonistic activity of trace elements in the cell e. g.
Zn-Se (22). On the other hand plasma, erythrocyte
and whole blood selenium deficiency could be ex-
plained as malabsorption of Se from the gastrointes-
tinal tract and/or increased renal clearance of Se (20,
23).
Since the glutathione peroxidase is one important
factor in the detoxication of organic lipid peroxides,
and because of the increase of lipid peroxidation in
trisomy 21 cells (24), we have investigated plasma
malondialdehyde concentration in Down's syndrome
patients. In our investigation we observed a decrease
of malondialdehyde concentration in the plasma of
trisomy 21 patients, compared with the control group
in both tested age groups. The decrease was 26.1%
in the younger patients and 38.4% in the adult pa-
tients. This is a surprising result, because earlier we
tested institutionalized Down's syndrome patients
(also inhabitants of Lodz) and we observed a 20%
increase in the lipid peroxide concentration of plasma
(13).
The significant changes of lipid peroxide concentra-
tion in plasma probably result from different envi-
ronmental conditions, and they represent a defensive
adaptation against oxidative damage. Probably un-
identified factors, such as an insufficient vitamin E
intake or a change in the composition or contents of
some fatty acids and phospholipids in the diet or in
the cells, also play an important role in the change of
the lipid peroxide concentration (10, 25).
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